On April 19, Qingdao Vland Biotech Inc(603739) announced the annual results of 2021, and the company achieved a revenue of 1.151 billion yuan, a year-on-year increase of 19.85%; The net profit attributable to shareholders of listed companies was 133 million yuan, a year-on-year increase of 21.65%. The company plans to distribute a cash dividend of 1.6 yuan (including tax) to all shareholders for every 10 shares. The first quarter report of 2022 disclosed by the company on the same day showed that the company achieved an operating revenue of 256 million yuan and a net profit attributable to shareholders of listed companies of 180839 million yuan.
Qingdao Vland Biotech Inc(603739) is mainly engaged in the R & D, production and sales of enzyme preparations, probiotics and animal health products. The rapid growth of enzyme preparations and probiotics is the main driving force for the growth of the company's revenue and profit in 2021. According to the data, the sales volume of the company's enzyme preparation sector reached 16200 tons in 2021, with a year-on-year increase of 35.02%; The operating revenue reached 430 million yuan, a year-on-year increase of 38.89%. The annual sales volume of micro ecology was 27300 tons, with a year-on-year increase of 19.09%; The operating revenue was 250 million yuan, a year-on-year increase of 16.58%.
While the traditional business grew steadily, the company also launched the human probiotic project in 2021. Probiotics can adjust human physiological functions, improve intestinal flora balance and improve body immunity. They are widely used in food, health care products, skin care products and other fields. They have broad market prospects and development prospects. The scale of products will be close to 85 billion yuan in 2020.
According to the industry situation of human probiotics and the development strategy of the company, the company adjusted the business plan of human probiotics business. The board of directors of the company also passed a resolution to terminate the implementation of the project of "technical transformation of 1000 tons of functional edible probiotic series products per year" and instead carry out the business through cooperation with international giants. During the reporting period, Weifang weizhilan Biotechnology Co., Ltd., a wholly-owned subsidiary of the company, introduced international investor ADM Singapore through capital increase to jointly expand the industrial chain of probiotics for human use. The products are promoted to the global market and are expected to be put into production and operation by the end of 2023 Qingdao Vland Biotech Inc(603739) said that the joint venture has obtained the land real estate property right certificate, the project construction is in orderly progress, and the future can be expected.
At the technical level, based on the original research and development strength of animal and plant microecology, the company has established the nutrition and health technology center. At present, it has formed four research and development platforms of strain identification, function verification, analysis and screening and strain improvement, and developed 16 probiotic strains with independent intellectual property rights, including alleviating gastrointestinal discomfort, improving skin condition, delaying aging, enhancing bone health, enhancing immune function Prevention of upper respiratory tract infection and anti-bacterial and anti-inflammatory. 38 invention patents related to probiotics, 12 utility model patents and 3 PCT patents have been applied. At present, 11 patents have been authorized, covering probiotic dietary supplements, functional raw materials of skin care products, food safety prediction technology and product application design innovation.
